Abstract
Summary
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
The global market for Phenylketonuria Therapeutic was estimated to be worth US$ 1000 million in 2023 and is forecast to a readjusted size of US$ 1783.2 million by 2030 with a CAGR of 8.6% during the forecast period 2024-2030
The phenylketonuria (PKU) therapeutic market is primarily driven by the increasing prevalence of PKU and the growing demand for effective treatments to manage this rare genetic disorder. PKU is characterized by the inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body, which can cause severe neurological and cognitive impairments if left untreated. As awareness about PKU and newborn screening programs improve, more patients are being diagnosed early, increasing the need for therapeutic interventions. However, the market also faces challenges, including the complexity of managing PKU through dietary restrictions and adherence to low-phenylalanine diets. This can be particularly challenging for young children and adults, impacting their quality of life and nutritional intake. Moreover, the limited availability of novel and more effective treatments for PKU poses a hurdle in addressing the unmet medical needs of patients. Addressing these challenges requires continued research and development of innovative therapies, including enzyme replacement therapies, gene therapies, and pharmacological interventions, to improve PKU management and alleviate dietary burdens. Additionally, raising awareness about PKU and its consequences among healthcare professionals and the general public is essential to facilitate early diagnosis and access to appropriate therapeutic options, ultimately driving the growth of the phenylketonuria therapeutic market and improving patient outcomes.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Phenylketonuria Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Phenylketonuria Therapeutic by region & country, by Type, and by Application.
The Phenylketonuria Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phenylketonuria Therapeutic.
Market Segmentation
By Company
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Segment by Type:
Medications
Supplements
Segment by Application
Household
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Phenylketonuria Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Phenylketonuria Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Phenylketonuria Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Phenylketonuria Therapeutic was estimated to be worth US$ 1000 million in 2023 and is forecast to a readjusted size of US$ 1783.2 million by 2030 with a CAGR of 8.6% during the forecast period 2024-2030
The phenylketonuria (PKU) therapeutic market is primarily driven by the increasing prevalence of PKU and the growing demand for effective treatments to manage this rare genetic disorder. PKU is characterized by the inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body, which can cause severe neurological and cognitive impairments if left untreated. As awareness about PKU and newborn screening programs improve, more patients are being diagnosed early, increasing the need for therapeutic interventions. However, the market also faces challenges, including the complexity of managing PKU through dietary restrictions and adherence to low-phenylalanine diets. This can be particularly challenging for young children and adults, impacting their quality of life and nutritional intake. Moreover, the limited availability of novel and more effective treatments for PKU poses a hurdle in addressing the unmet medical needs of patients. Addressing these challenges requires continued research and development of innovative therapies, including enzyme replacement therapies, gene therapies, and pharmacological interventions, to improve PKU management and alleviate dietary burdens. Additionally, raising awareness about PKU and its consequences among healthcare professionals and the general public is essential to facilitate early diagnosis and access to appropriate therapeutic options, ultimately driving the growth of the phenylketonuria therapeutic market and improving patient outcomes.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Phenylketonuria Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Phenylketonuria Therapeutic by region & country, by Type, and by Application.
The Phenylketonuria Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phenylketonuria Therapeutic.
Market Segmentation
By Company
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Segment by Type:
Medications
Supplements
Segment by Application
Household
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Phenylketonuria Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Phenylketonuria Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Phenylketonuria Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Phenylketonuria Therapeutic Product Introduction
1.2 Global Phenylketonuria Therapeutic Market Size Forecast
1.3 Phenylketonuria Therapeutic Market Trends & Drivers
1.3.1 Phenylketonuria Therapeutic Industry Trends
1.3.2 Phenylketonuria Therapeutic Market Drivers & Opportunity
1.3.3 Phenylketonuria Therapeutic Market Challenges
1.3.4 Phenylketonuria Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Phenylketonuria Therapeutic Players Revenue Ranking (2023)
2.2 Global Phenylketonuria Therapeutic Revenue by Company (2019-2024)
2.3 Key Companies Phenylketonuria Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies Phenylketonuria Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of Phenylketonuria Therapeutic
2.6 Phenylketonuria Therapeutic Market Competitive Analysis
2.6.1 Phenylketonuria Therapeutic Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Phenylketonuria Therapeutic Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phenylketonuria Therapeutic as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Medications
3.1.2 Supplements
3.2 Global Phenylketonuria Therapeutic Sales Value by Type
3.2.1 Global Phenylketonuria Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Phenylketonuria Therapeutic Sales Value, by Type (2019-2030)
3.2.3 Global Phenylketonuria Therapeutic Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Household
4.1.2 Hospital
4.2 Global Phenylketonuria Therapeutic Sales Value by Application
4.2.1 Global Phenylketonuria Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Phenylketonuria Therapeutic Sales Value, by Application (2019-2030)
4.2.3 Global Phenylketonuria Therapeutic Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Phenylketonuria Therapeutic Sales Value by Region
5.1.1 Global Phenylketonuria Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Phenylketonuria Therapeutic Sales Value by Region (2019-2024)
5.1.3 Global Phenylketonuria Therapeutic Sales Value by Region (2025-2030)
5.1.4 Global Phenylketonuria Therapeutic Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Phenylketonuria Therapeutic Sales Value, 2019-2030
5.2.2 North America Phenylketonuria Therapeutic Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Phenylketonuria Therapeutic Sales Value, 2019-2030
5.3.2 Europe Phenylketonuria Therapeutic Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Phenylketonuria Therapeutic Sales Value, 2019-2030
5.4.2 Asia Pacific Phenylketonuria Therapeutic Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Phenylketonuria Therapeutic Sales Value, 2019-2030
5.5.2 South America Phenylketonuria Therapeutic Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Phenylketonuria Therapeutic Sales Value, 2019-2030
5.6.2 Middle East & Africa Phenylketonuria Therapeutic Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Phenylketonuria Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Phenylketonuria Therapeutic Sales Value
6.3 United States
6.3.1 United States Phenylketonuria Therapeutic Sales Value, 2019-2030
6.3.2 United States Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Phenylketonuria Therapeutic Sales Value, 2019-2030
6.4.2 Europe Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Phenylketonuria Therapeutic Sales Value, 2019-2030
6.5.2 China Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.5.3 China Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Phenylketonuria Therapeutic Sales Value, 2019-2030
6.6.2 Japan Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Phenylketonuria Therapeutic Sales Value, 2019-2030
6.7.2 South Korea Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Phenylketonuria Therapeutic Sales Value, 2019-2030
6.8.2 Southeast Asia Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Phenylketonuria Therapeutic Sales Value, 2019-2030
6.9.2 India Phenylketonuria Therapeutic Sales Value by Type (%), 2023 VS 2030
6.9.3 India Phenylketonuria Therapeutic Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Biomarin
7.1.1 Biomarin Profile
7.1.2 Biomarin Main Business
7.1.3 Biomarin Phenylketonuria Therapeutic Products, Services and Solutions
7.1.4 Biomarin Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.1.5 Biomarin Recent Developments
7.2 Mead Johnson
7.2.1 Mead Johnson Profile
7.2.2 Mead Johnson Main Business
7.2.3 Mead Johnson Phenylketonuria Therapeutic Products, Services and Solutions
7.2.4 Mead Johnson Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.2.5 Mead Johnson Recent Developments
7.3 Abbott
7.3.1 Abbott Profile
7.3.2 Abbott Main Business
7.3.3 Abbott Phenylketonuria Therapeutic Products, Services and Solutions
7.3.4 Abbott Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.3.5 Nutricia Recent Developments
7.4 Nutricia
7.4.1 Nutricia Profile
7.4.2 Nutricia Main Business
7.4.3 Nutricia Phenylketonuria Therapeutic Products, Services and Solutions
7.4.4 Nutricia Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.4.5 Nutricia Recent Developments
7.5 Dr. Schär
7.5.1 Dr. Schär Profile
7.5.2 Dr. Schär Main Business
7.5.3 Dr. Schär Phenylketonuria Therapeutic Products, Services and Solutions
7.5.4 Dr. Schär Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.5.5 Dr. Schär Recent Developments
7.6 Vitaflo
7.6.1 Vitaflo Profile
7.6.2 Vitaflo Main Business
7.6.3 Vitaflo Phenylketonuria Therapeutic Products, Services and Solutions
7.6.4 Vitaflo Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.6.5 Vitaflo Recent Developments
7.7 Cambrooke
7.7.1 Cambrooke Profile
7.7.2 Cambrooke Main Business
7.7.3 Cambrooke Phenylketonuria Therapeutic Products, Services and Solutions
7.7.4 Cambrooke Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.7.5 Cambrooke Recent Developments
7.8 PKU Perspectives
7.8.1 PKU Perspectives Profile
7.8.2 PKU Perspectives Main Business
7.8.3 PKU Perspectives Phenylketonuria Therapeutic Products, Services and Solutions
7.8.4 PKU Perspectives Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.8.5 PKU Perspectives Recent Developments
7.9 Firstplay Dietary
7.9.1 Firstplay Dietary Profile
7.9.2 Firstplay Dietary Main Business
7.9.3 Firstplay Dietary Phenylketonuria Therapeutic Products, Services and Solutions
7.9.4 Firstplay Dietary Phenylketonuria Therapeutic Revenue (US$ Million) & (2019-2024)
7.9.5 Firstplay Dietary Recent Developments
8 Industry Chain Analysis
8.1 Phenylketonuria Therapeutic Industrial Chain
8.2 Phenylketonuria Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Phenylketonuria Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 Phenylketonuria Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer